Peptide activators of VEGF

Details Peptide activators of VEGF Peptide activators of VEGF

2006-05-30

2006-05-30

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S402000, C435S440000

Reexamination Certificate

active

07053046

ABSTRACT:
The invention provides peptide inhibitors that inhibit ubiquitination of hypoxia inducible factor 1 alpha (HIP 1-α) and thereby activate transcription of erythropoietin (EPO), vascular endothelial growth factor (VEGF), and certain glycolytic enzymes. The invention further provides formulations containing the present peptides and methods of using the present peptides for therapeutic purposes. Such therapeutic purposes include stimulating angiogenesis in injured tissues such as chronic wounds, heart tissues injured by ischemia or heart attack, and neural tissues injured by stroke.

REFERENCES:
patent: 6124131 (2000-09-01), Semenza
patent: 6566088 (2003-05-01), McKnight et al.
patent: WO 0069908 (2000-11-01), None
Jaakkola P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O23-regulated prolyl hydroxylation. Science. vol. 292, pp. 468-472.
Jones, A. et al. (2001) Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res. 7, 1263-1272.
Yu, F. et al. (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. vol. 98, pp. 9630-9635.
Bruick, R. et al. (2001) conserved family of prolyl-4-hydroxylases that modify HIF. Science. vol. 294, pp. 1337-1340.
Cockman, M.,et al. ,“Hyposix Inducible Factor-alpha Binding and Ubiqitylation by the von Hippel-Lindau Tumor Supressor Protein”,The Journal of Biological Chemistry, 275(33), (2000),pp. 25733-25741.
Der, S.,et al. ,“Identification of genes differentially regulated by interferon alpha, B, or y using oligonucleotide arrays”,Proc. Natl. Acad, Sci. USA, 95, (1998), pp. 15623-15628.
Gradin, K.,et al. ,“Repression of Dioxin Signal Transduction in Fibroblasts”,The Journal of Biological Chemistry, 274(19), (1999),pp. 13511-13518.
Hossain, M.,et al. ,“Induction of Vascular Endothelial Growth Factor in Human Astrocytes by Lead”,the Journal of Biological Chemistry, 274(36), (2000),pp. 27874-27882.
Huang, L.,et al. ,“Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway”,Proc. Natl. Acad. Sci. USA. 95, (1998),pp. 7987-7992.
Iyer, N.,et al. ,“Celluar and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha”,Genes&Development, 12, (1998),pp. 149-162.
Kamura, T.,et al. ,“Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex”,PNAS, 97(19), (2000),pp. 10430-10435.
Mathupala, S.,et al. ,“Glucose Catabolism in Cancer Cells: Indentification and Charcterization of A Marked Activation Response of The Type II Hexokinase Gene to Hypoxic Condition”,The American Society for Biochemistry and Molecular Biology, Inc.,pp. 1-24.
Scheid, A.,et al. ,“Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair”,Pediatr. Surg. Int., 16, (2000),pp. 232-236.
Semenza, G.,“HIF-1: mediator of physiological and pathophysiological to hypoxia”,J. Appl. Physiol., 88, (2000),pp. 1474-1480.
Sutter, C.,et al. ,“Hypoxia-inducible factor 1alpha protein expression in controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations”,PNAS, 97(9), (2000),pp. 4748-4753.
Takahashi, Y.,et al. ,“Hypoxic Induction of Prolyl 4-Hydroxylase alpha(I) in cultured cells”,The Journal of Biological Chemistry, 275(19), (2000),pp. 14139-14146.
Tanimoto, K.,et al. ,“Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein”,The EMBO Journal, 19(16), (2000),pp. 4298-4309.
Wenger, R.,“Review—Mammalian Oxygen Sensing, Signalling and Gene Regulation”,The Journal of Experimental Biology, 203, (2000),pp. 1253-1263.
Yu, F.,et al. ,“HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation”,PNAS, 98(17), (2001),pp. 9630-9635.
Zhong, H.,et al. ,“Overexpression of Hypoxia-inducible Factor 1alpha in Common Human Cancers and Their Metastases”,Cancer Research, 59, (1999),pp. 5830-5835.
Gudmundsson, G. H., et al., “Structure of the Gene for Porcine Peptide Antibiotic PR-39, a Cathelin Gene Family Member: Comparative Mapping of the Locus for the Human Peptide Antibiotic Fall-39”,Proc. Natl. Acad. Sci. USA, 92, (1995), 7085-7089.
Krek, W., “VHL Takes HIF's Breath Away”,Nature Cell Biology, 2, (2000) E1-E3.
Li, J., et al., “PR39, a Peptide Regulator of Angiogenesis”,Nature Medicine, 6, (2000), 49-55.
Lisztwan, J., et al., “The Von Hippel-Lindau Tumor Suppressor Protein is a Component of an E3 Ubiquitin-Protein Ligase Activity”,Gene and Development, 13, (1999), 1822-1833.
Ratliffe, P. J., et al., “Oxygen Sensing, Hypoxia-Inducible Factor-1 and the Regulation of Mammalian Gene Expression”,The Journal of Experimental Biology, 201, (1998), 1153-1162.

Affiliated with

Also associated with

Rating

Peptide activators of VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide activators of VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide activators of VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3539231